华熙生物科技股份有限公司发布2025年度业绩快报。公告显示，2025年度公司实现营业总收入42.17亿元，同比下降21.49%；实 现归属于母公司所有者的净利润2.91亿元，同比增长67.03%；扣除非经常性损益后的净利润1.88亿元，同比增长75.28%。在营业 收入阶段性承压的背景下，公司盈利能力和经营质量实现显著提升。 从整体表现来看，2025年华熙生物延续了近年来由规模扩张向质量提升转型的发展方向，通过组织调整、业务结构优化和运营 效率提升，实现利润与净资产收益率的同步改善。报告期内，公司加权平均净资产收益率达到4.17%，较上年同期提升1.62个百 分点，反映出资本回报能力持续增强。 | | | | 单位:人民币元 | | --- | --- | --- | --- | | 项目 | 本报告期 | 上年同期 | 增减变动幅度 (%) | | 营业总收入 | 4.216.838.580.89 | 5,370,770,254.64 | -21.49 | | 营业利润 | 333.900.379.48 | 215.939.708.29 | 54.63 | | 利润总额 | 333.788.862.03 | ...

华熙生物科技股份有限公司发布2025年度业绩快报。公告显示，2025年度公司实现营业总收入42.17亿 元，同比下降21.49%；实现归属于母公司所有者的净利润2.91亿元，同比增长67.03%；扣除非经常性损 益后的净利润1.88亿元，同比增长75.28%。在营业收入阶段性承压的背景下，公司盈利能力和经营质量 实现显著提升。 从整体表现来看，2025年华熙生物延续了近年来由规模扩张向质量提升转型的发展方向，通过组织调 整、业务结构优化和运营效率提升，实现利润与净资产收益率的同步改善。报告期内，公司加权平均净 资产收益率达到4.17%，较上年同期提升1.62个百分点，反映出资本回报能力持续增强。 此外，公司持续推进数字化与AI技术在生产制造、供应链管理及内部运营等环节的应用，通过流程优 化与数据治理提升整体运营效率，有望进一步推动经营质量的提升。 2025年度，公司以"敏捷经营、增长增效"为核心，通过组织架构系统性优化、职能协同整合、运营模式 升级，推动公司从"规模扩张"向"质量增长"转型。 近年来，华熙生物持续拓展在生命健康衰老干预相关领域的技术与产品布局，推动科技逻辑走向可感知 的产业应用与消费场景。从专 ...

证券日报网讯 2月12日，中牧股份在互动平台回答投资者提问时表示，公司部分产品生产技术符合合成 生物技术特征。 （文章来源：证券日报） ...

格隆汇2月12日丨中牧股份(600195.SH)在投资者互动平台表示，公司部分产品生产技术符合合成生物技 术特征。 ...

Core Insights - The Chinese nutrition and health industry is experiencing a surge in IPO activities, indicating a shift from local operations to global expansion and a focus on scientific validation [4][5]. IPO Developments - In 2025, several companies in the nutrition and health sector are set to go public, covering the entire supply chain from raw materials to manufacturing and branding [4]. - Dongpeng Beverage plans to list on the Hong Kong Stock Exchange in early 2026, aiming to raise over HKD 10.1 billion, marking the largest IPO in the non-alcoholic beverage sector in Hong Kong history [4]. - Xianle Health is advancing its H-share listing while optimizing its global CDMO platform by divesting non-core assets [4]. - Ruoyuchen has submitted its application to the Hong Kong Stock Exchange, focusing on its proprietary brand FineNutri to transition from a service provider to a brand owner [4]. - Other companies like Jiyuan Group and Hengmei Health are also pursuing listings to enhance their production capacities and market presence [4][5]. Regulatory Updates - The National Market Supervision Administration has released several guidelines and regulations affecting the health and nutrition sector, including the review of special medical formula food production licenses and the management of live-streaming e-commerce [6][7]. - New regulations have been introduced to ensure compliance in the marketing of health products, including a ban on certain food sales in live-streaming environments [6]. Market Trends - There is a notable increase in demand for health supplements, with sales of ginseng and other tonic products rising by 55% year-on-year during the New Year holiday [17]. - The import of medical and health products has also seen significant growth, with a 70.4% increase in imports in Hubei province in 2025 [17]. Industry Insights - The current wave of capital influx is not merely for financing but signals a critical transition in the industry towards scientific validation and global operations [4]. - Companies with genuine research capabilities, compliant product systems, and international perspectives are expected to gain a competitive edge in high-quality development [4].

1月30日，华熙生物发布2025年年度业绩预增公告。公告显示，公司预计2025年实现归属于母公司所有 者的净利润2.70亿元至3.20亿元，同比增长54.93%到83.63%；扣除非经常性损益后的净利润1.67亿元至 2.17亿元，同比增长55.68%到102.29%。公司盈利能力实现显著提升，体现出经营质量持续改善的发展 成效。 2025年业绩增长是华熙生物组织优化、业务聚焦、科技创新与数字化赋能协同发力的综合成果，也是长 期坚持高质量发展和核心能力建设的阶段性体现。未来，公司将继续坚持以科技创新为核心，以合成生 物技术和产业化平台为支撑，持续夯实长期竞争优势，推动经营质量和可持续发展能力稳步提升。 财经频道更多独家策划、专家专栏，免费查阅>> 责任编辑：山上 在业务运营层面，华熙生物以专业化聚焦发展方向，持续优化业务结构和资源配置。通过加强供应链协 同管理、推进库存结构优化，将更多资源投入到具备长期竞争优势的核心领域。2025年销售费用同比下 降超过30%，在收入承压的背景下实现盈利能力持续改善。 在研发和科技创新层面，华熙生物基于糖类物质在细胞分化与信号机制中的关键作用，围绕细胞外基 质、细胞间通讯、细 ...

Investment Rating - The investment rating for the company is "Buy" (首次) [1] Core Insights - The company is a leading small molecule CDMO with over 25 years of experience, currently transitioning from a single small molecule business to a dual-driven model of "small molecule + emerging business" [5][17] - The new business segment is experiencing rapid growth, contributing significantly to revenue, while traditional business remains resilient [5][6] - The company is expected to achieve net profits of 1.16 billion, 1.30 billion, and 1.51 billion yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 3.23, 3.59, and 4.18 yuan [5] Financial Summary and Valuation Metrics - Revenue projections for 2025, 2026, and 2027 are 6.66 billion, 7.69 billion, and 8.94 billion yuan respectively, with year-over-year growth rates of 14.7%, 15.4%, and 16.3% [8] - The company’s gross margin is projected to be around 42% for 2025, with a net margin of 17.5% [8] - The current P/E ratios are 31.0, 27.8, and 23.9 for 2025, 2026, and 2027 respectively [8] Business Development and Strategy - The company is focusing on expanding its capabilities in the peptide and small nucleic acid sectors, with significant investments in production capacity [6][79] - As of H1 2025, the new business segment generated 756 million yuan in revenue, a 51.22% increase year-over-year, accounting for 23.71% of total revenue [6] - The company has established partnerships with major pharmaceutical companies, enhancing its market presence and customer base [44] Industry Trends - The global healthcare investment environment is gradually recovering, with a total investment of 63.88 billion USD in 2025, marking a 10.13% increase year-over-year [47] - The domestic healthcare investment market is also improving, with a total of 73.78 billion yuan in 2025, a 39.05% increase year-over-year [53] - The global CDMO market is expected to grow significantly, with the small molecule CDMO/CMO market projected to reach 112 billion USD by 2029, growing at a CAGR of 16.6% [65]

Core Viewpoint - Fuxiang Pharmaceutical is expected to significantly reduce its net loss in 2025, projecting a loss of 39 million to 57 million yuan, with a potential turnaround to profitability in Q4, driven by the synergy of its three main business segments: new energy, pharmaceutical manufacturing, and synthetic biology [1] Group 1: Business Performance - The new energy lithium battery electrolyte additive business is identified as the core driver of performance growth in 2025, benefiting from rising demand in the power battery and energy storage markets, leading to a substantial price increase for products like VC and FEC in Q4 [1] - The pharmaceutical manufacturing segment has optimized its operations despite intense market competition, with a decrease in the price of key raw materials like 6-APA alleviating cost pressures and improving gross margins [2] - The synthetic biology segment achieved significant milestones in 2025, obtaining key certifications that enable the transition from laboratory research to large-scale production, indicating a successful compliance pathway [2] Group 2: Future Outlook - For 2026, the company aims to consolidate its market position in the pharmaceutical sector while focusing on cost reduction and efficiency improvements [3] - The company plans to capitalize on the rising product prices in the new energy sector by enhancing production capacity through technological upgrades [3] - The company will accelerate the development of the synthetic biology protein project, expanding its application scenarios and enhancing its market presence both domestically and internationally [3]

Group 1 - The article discusses the recruitment of 7 postdoctoral researchers for projects related to "Basic and Interdisciplinary Breakthroughs (Synthetic Multi-cell Genomes)" and "National Major Instrument Development Projects (High-Precision Synthesis Systems for Long Fragments of DNA)" [3] - Candidates with backgrounds in epigenomics, strain construction, and enzyme catalysis are particularly encouraged to apply, especially those who have recently completed or are about to complete their PhD [3] - The age limit for applicants is generally set at 35 years, and candidates should possess strong academic qualifications and research capabilities [3] Group 2 - The hiring package includes competitive salary and performance rewards, support for applying to national postdoctoral programs, and benefits such as children's education and social insurance [4] - The institution offers assistance in applying for various research projects, including the National Natural Science Foundation and postdoctoral programs [4] - A good research platform and opportunities for international collaboration and exchange are provided [4] Group 3 - Application materials must be combined into a single PDF and sent to the specified email address, with a clear subject line indicating the position and applicant's name [5] - Required documents include a personal resume, a personal statement outlining research interests and development plans, and contact information for three referees along with recommendation letters [5] - The recruitment is ongoing until positions are filled, and self-recommendations are welcomed [5]

对此，中国科学院深圳先进技术研究院和深圳大学联合科研团队，以人体肠道常见微生物大肠杆菌 为基础，设计了一种多功能的"智能活胶水"。当肠道内特定部位出血时，系统被快速激活，随后分泌出 一种来源于海洋藤壶的黏性蛋白，可以精准地在出血部位形成"密封层"，还能同步释放修复因子，实现 定位与治疗的协同。 "我们把这种经过改造的微生物培养在液体里，通过口服方式进入肠道，激活后形成膜状形态，黏 附在肠道特定出血部位，起到止血和修复损伤的作用。"研究负责人、中国科学院深圳先进技术研究院 研究员钟超说。 中国科学院深圳先进技术研究院和深圳大学联合科研团队从海洋藤壶、沙堡蠕虫等动物身上获得灵 感，利用合成生物技术研发了一种能够感知肠道出血信号、修复肠道黏膜损伤的"智能活胶水"，为炎症 性肠病的靶向治疗提供了新策略。相关研究成果北京时间1月19日下午在线发表于国际期刊《自然-生物 技术》。 科研人员在动物模型中验证了上述结论，目前已开展免疫相容性评估，后续将推进临床转化研究， 未来有望为炎症性肠病患者提供靶向治疗的可能。 据科研人员介绍，炎症性肠病患者常常伴随肠道黏膜反复损伤、慢性炎症、出血等症状，一般需要 使用医用粘合剂来止血和 ...